NDA 021318 · Lilly
Forteo
Teriparatide · Subcutaneous · Parathyroid Hormone Analog
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Nov 26, 2002
Approved uses
3
Original approval plus efficacy supplements
Registered trials
155
34 Phase 3, 5 recruiting
FAERS reports
112,496
41,897 serious, 5,314 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 3, 2026.
FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. FORTEO is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )
Mechanism: Endogenous 84-amino acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Physiological actions of PTH include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. The biological actions of PTH and teriparatide are mediated through binding to specific high-affinity cell-surface receptors. Teriparatide and the 34 N-terminal amino acids of PTH bind to these receptors with the same affinity and have the same physiological actions on bone and kidney. Teriparatide is not...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 16, 2020 Supplement 54 · Efficacy LetterLabelMedication Guide
- Jul 22, 2009 Supplement 12 · Efficacy LetterLabel
- Nov 26, 2002 Original approval · Type 3 - New Dosage Form LabelReviewLetter
2 products under this application
- FORTEO · TERIPARATIDE 0.56MG/2.24ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
- FORTEO · TERIPARATIDE 0.75MG/3ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Teriparatide" as an intervention, any sponsor and status, largest first.
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefracturePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05866029 · 2,478 participants (planned) · Start May 26, 2023 · Primary completion Sep 30, 2026
Drug: Denosumab; Teriparatide · For: Osteoporotic Fractures
Sites: Beijing, China; Changchun, China; Changsha, China · 58 sites in all
- Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal WomenPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01343004 · 2,463 participants · Start Apr 2011 · Primary completion Oct 2014
Drug: Placebo; BA058 80 mcg and 1 more · For: Osteoporosis; Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Miami, Florida; North Miami, Florida · 28 sites in all
- Effects of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00670501 · 1,637 participants · Start Aug 1996 · Primary completion Apr 1999
Drug: teriparatide; teriparatide and 3 more · For: Osteoporosis, Postmenopausal
Sites: Boston, Massachusetts; Capital Federal, Argentina; Nedlands, Australia · 17 sites in all
- VERtebral Fracture Treatment Comparisons in Osteoporotic WomenPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01709110 · 1,366 participants · Start Oct 2012 · Primary completion Jul 2016
Drug: Teriparatide; Risedronate and 3 more · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Concord, California; Fresno, California · 103 sites in all
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00191425 · 810 participants · Start Aug 2002
Drug: Teriparatide; Raloxifene · For: Osteoporosis, Postmenopausal
Sites: Bad Pyrmont, Germany
- Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00343252 · 712 participants · Start Jun 2006 · Primary completion Jun 2009
Drug: teriparatide; risedronate and 2 more · For: Osteoporosis, Postmenopausal; Back Pain; Spinal Fracture
Sites: Birmingham, Alabama; Montgomery, Alabama; Peoria, Arizona · 72 sites in all
- A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.Pivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT00471237 · 564 participants · Start May 14, 2007 · Primary completion Dec 26, 2008
Drug: Ronacaleret; Teriparatide and 1 more · For: Osteoporosis
Sites: Oakland, California; Palm Desert, California; Walnut Creek, California · 49 sites in all
- To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture RiskPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07028320 · 493 participants · Start Dec 3, 2021 · Primary completion Dec 30, 2023
Drug: SAL056 (56.5μg); Alendronate · For: Postmenopausal Women With Osteoporosis
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea9,026
- arthralgia8,725
- pain in extremity8,375
- dizziness8,337
- fall7,933
- pain7,575
- fatigue7,225
- back pain5,948
- muscle spasms5,753
- malaise5,689
- headache5,528
- asthenia5,454
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6,414 |
| 2005 | 4,792 |
| 2006 | 2,193 |
| 2007 | 2,193 |
| 2008 | 2,133 |
| 2009 | 3,068 |
| 2010 | 3,799 |
| 2011 | 5,405 |
| 2012 | 6,250 |
| 2013 | 2,648 |
| 2014 | 1,297 |
| 2015 | 44,975 |
| 2016 | 2,140 |
| 2017 | 4,040 |
| 2018 | 4,898 |
| 2019 | 4,011 |
| 2020 | 1,957 |
| 2021 | 1,813 |
| 2022 | 1,581 |
| 2023 | 1,757 |
| 2024 | 1,839 |
| 2025 | 2,090 |
| 2026 | 1,203 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Forteo (Teriparatide)
2024 spending
$266M
Beneficiaries
11,433
67,653 claims
Per beneficiary
$23,297
$1,571.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $457,345,880 |
| 2021 | $371,324,574 |
| 2022 | $368,538,667 |
| 2023 | $425,012,975 |
| 2024 | $266,352,818 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
Khan AA, Morrison A, Hanley DA, et al. · J Bone Miner Res 2015 · Systematic Review, Consensus Statement
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, et al. · JAMA 2016 · Clinical Trial, Phase III, Multicenter Study
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ, Tsai JN, Uihlein AV, et al. · Lancet 2015 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH, Mayer B, Hussein H, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
Li M, Ge Z, Zhang B, et al. · Arch Osteoporos 2024 · Comparative Study, Meta-Analysis
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.